Similar articles

Abstract: Mitochondrion is a semi-autonomous organelle, important for cell energy metabolism, apoptosis, the production of reactive oxygen species (ROS), and Ca²⁺ homeostasis. mitochondrial DNA (mtDNA) mutation is one of the primary factors in mitochondrial disorders. Though much progress has been made, there remain many difficulties in constructing cell models for mitochondrial diseases. This seriously restricts studies related to targeted drug discovery and the mechanism and therapy for such diseases. Here we summarize the characteristics of patient-specific immortalized lymphoblastoid cells, fibroblastoid cells, cytoplasmic hybrid (cybrid) cell lines, and induced pluripotent stem cells (iPSCs)-derived differentiation cells in the study of mitochondrial disorders, as well as offering discussion of roles and advances of these cell models, particularly in the screening of drugs.

线粒体疾病细胞模型及其药物筛选

[1]Aiyar RS, Bohnert M, Duvezin-Caubet S, et al., 2014. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat Commun, 5:5585.

[2]Amoli MM, Carthy D, Platt H, et al., 2008. EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int J Epidemiol, 37(Suppl 1):i41-i45. 


[3]Barrow JJ, Balsa E, Verdeguer F, et al., 2016. Bromodomain inhibitors correct bioenergetic deficiency caused by mitochondrial disease complex I mutations. Mol Cell, 64(1):163-175.

[4]Boulting GL, Kiskinis E, Croft GF, et al., 2011. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol, 29(3):279-286.

[5]Cámara Y, González-Vioque E, Scarpelli M, et al., 2014. Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome. Hum Mol Genet, 23(9):2459-2467.

[6]Cherry ABC, Gagne KE, Mcloughlin EM, et al., 2013. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells, 31(7):1287-1297.

[7]Chin RM, Panavas T, Brown JM, et al., 2018. Patient-derived lymphoblastoid cell lines harboring mitochondrial DNA mutations as tool for small molecule drug discovery. BMC Res Notes, 11:205.

[8]Chou SJ, Tseng WL, Chen CT, et al., 2016. Impaired ROS scavenging system in human induced pluripotent stem cells generated from patients with MERRF syndrome. Sci Rep, 6:23661.

[9]Chou SJ, Ko YL, Yang YH, et al., 2018. Generation of two isogenic human induced pluripotent stem cell lines from a 15 year-old female patient with MERRF syndrome and A8344G mutation of mitochondrial DNA. Stem Cell Res, 30:201-205.

[10]Cotán D, Cordero MD, Garrido-Maraver J, et al., 2011. Secondary coenzyme Q₁₀ deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J, 25(8):2669-2687.

[11]Couplan E, Aiyar RS, Kucharczyk R, et al., 2011. A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA, 108(29):11989-11994.

[12]de la Mata M, Garrido-Maraver J, Cotán D, et al., 2012. Recovery of MERRF fibroblasts and cybrids pathophysiology by coenzyme Q₁₀. Neurotherapeutics, 9(2):446-463.

[13]Ebert AD, Yu JY, Rose FF Jr, et al., 2009. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457(7227):277-280.

[14]Farrar GJ, Chadderton N, Kenna PF, et al., 2013. Mitochondrial disorders: aetiologies, models systems, and candidate therapies. Trends Genet, 29(8):488-497.

[15]Fujikura J, Nakao K, Sone M, et al., 2012. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia, 55(6):1689-1698.

[16]Garrido-Maraver J, Cordero MD, Moñino ID, et al., 2012. Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease. Br J Pharmacol, 167(6):1311-1328.

[17]Holt IJ, Harding AE, Morgan-Hughes JA, 1988. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature, 331(6158):717-719.

[18]Howlett EH, Jensen N, Belmonte F, et al., 2017. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Hum Mol Genet, 26(22):4340-4351.

[19]Hsu YH, Wu YT, Huang CY, et al., 2017. Generation of an induced pluripotent stem cell line from a 39-year-old female patient with severe-to-profound non-syndromic sensorineural hearing loss and a A1555G mutation in the mitochondrial MTRNR1 gene. Stem Cell Res, 25:245-249.

[20]Inak G, Lorenz C, Lisowski P, et al., 2017. Concise review: induced pluripotent stem cell-based drug discovery for mitochondrial disease. Stem Cells, 35(7):1655-1662.

[21]Jeong MH, Kim JH, Seo KS, et al., 2014. β-Lapachone attenuates mitochondrial dysfunction in MELAS cybrid cells. Biochem Biophys Res Commun, 454(3):417-422.

[22]Jing R, Corbett JL, Cai J, et al., 2018. A screen using iPSC-derived hepatocytes reveals NAD⁺ as a potential treatment for mtDNA depletion syndrome. Cell Rep, 25(6):1469-1484.e5.

[23]Kang E, Wu J, Gutierrez NM, et al., 2016. Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. Nature, 540(7632):270-275.

[24]Kang JF, Tang BS, Guo JF, 2016. The progress of induced pluripotent stem cells as models of Parkinson’s disease. Stem Cells Int, 2016:4126214.

[25]Koopman WJH, Beyrath J, Fung CW, et al., 2016. Mitochondrial disorders in children: toward development of small-molecule treatment strategies. EMBO Mol Med, 8(4):311-327.

[26]https://doi.org/10.15252/emmm.201506131

[27]Li SS, Pan HY, Tan C, et al., 2018. Mitochondrial dysfunctions contribute to hypertrophic cardiomyopathy in patient iPSC-derived cardiomyocytes with MT-RNR2 mutation. Stem Cell Reports, 10(3):808-821.

[28]Lorenz C, Lesimple P, Bukowiecki R, et al., 2017. Human iPSC-derived neural progenitors are an effective drug discovery model for neurological mtDNA disorders. Cell Stem Cell, 20(5):659-674.e9.

[29]Lu HE, Yang YP, Chen YT, et al., 2018. Generation of patient-specific induced pluripotent stem cells from Leber’s hereditary optic neuropathy. Stem Cell Res, 28:56-60.

[30]Ma H, Folmes CDL, Wu J, et al., 2015. Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature, 524(7564):234-238.

[31]Matsubara M, Kanda H, Imamura H, et al., 2018. Analysis of mitochondrial function in human induced pluripotent stem cells from patients with mitochondrial diabetes due to the A3243G mutation. Sci Rep, 8(1):949.

[32]Mattiazzi M, Vijayvergiya C, Gajewski CD, et al., 2004. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum Mol Genet, 13(8):869-879.

[33]Pfeffer G, Horvath R, Klopstock T, et al., 2013. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol, 9(8):474-481.

[34]Reardon S, 2016. Reports of ‘three-parent babies’ multiply. Nature News [Accessed on Apr. 11, 2019].

[35]Saada A, 2011. The use of individual patient’s fibroblasts in the search for personalized treatment of nuclear encoded OXPHOS diseases. Mol Genet Metab, 104(1-2):39-47.

[36]Sala L, Bellin M, Mummery CL, 2017. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come? Br J Pharmacol, 174(21):3749-3765.

[37]Sun JJ, Zhao XX, Qiao LH, et al., 2016. Cellular models for mitochondrial DNA-based diseases: lymphoblastoid cell lines and transmitochondrial cybrids. Hereditas (Beijing), 38(7):666-673 (in Chinese).

[38]https://doi.org/10.16288/j.yczz.16-085

[39]Wallace DC, 2013. A mitochondrial bioenergetic etiology of disease. J Clin Invest, 123(4):1405-1412.

[40]Wallace DC, Fan WW, 2009. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev, 23(15):1714-1736.

[41]Wallace DC, Singh G, Lott MT, et al., 1988. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science, 242(4884):1427-1430.

[42]Wilkins HM, Carl SM, Swerdlow RH, 2014. Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biol, 2:619-631.

[43]Wu J, Ocampo A, Belmonte JCI, 2016. Cellular metabolism and induced pluripotency. Cell, 166(6):1371-1385.

[44]Wu YR, Wang AG, Chen YT, et al., 2018. Bioactivity and gene expression profiles of hiPSC-generated retinal ganglion cells in MT-ND4 mutated Leber’s hereditary optic neuropathy. Exp Cell Res, 363(2):299-309.

[45]Yamanaka S, 2007. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell, 1(1):39-49.

[46]Yan QF, Guan MX, 2008. Nuclear genes and mitochondrial genes associated with mitochondrial diseases. Chin Bull Life Sci, 20(4):497-505 (in Chinese).